Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RADIUS HEALTH, INC.

(RDUS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
16.03(c) 14.93(c) 14.85(c) 14.38(c) 8.01(c) Last
383 049 651 367 454 724 801 263 9 876 147 Volume
+3.15% -6.86% -0.54% -3.16% -44.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 228 M - -
Net income 2021 -62,0 M - -
Net Debt 2021 170 M - -
P/E ratio 2021 -6,05x
Yield 2021 -
Sales 2022 276 M - -
Net income 2022 -4,77 M - -
Net Debt 2022 139 M - -
P/E ratio 2022 -300x
Yield 2022 -
Capitalization 379 M 379 M -
EV / Sales 2021 2,41x
EV / Sales 2022 1,88x
Nbr of Employees 310
Free-Float 98,9%
More Financials
Company
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in... 
More about the company
Ratings of Radius Health, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about RADIUS HEALTH, INC.
08:48aMenarini Group - Positive EMERALD Trial Results for Elacestrant Presented at San Antoni..
AQ
07:34aHC Wainwright Adjusts Radius Health's Price Target to $10 From $23, Keeps Neutral Ratin..
MT
12/08Health Care Stocks Lifting Broader Wednesday Markets Higher in Late Trade
MT
12/08Top Midday Decliners
MT
12/08Radius Health's Study of Potential Treatment for Postmenopausal Women With Osteoporosis..
MT
12/08Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer S..
AQ
12/08Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal S..
AQ
12/08Radius Health to Host Conference Call Today, Wednesday, December 8, 2021
AQ
12/06BofA Reinstates Radius Health at Underperform Rating With $16 Price Target
MT
11/15RADIUS HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
11/15Radius Health, Inc. Announces Executive Changes
CI
11/11Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference
AQ
11/09HC Wainwright Adjusts Price Target on Radius Health to $23 From $26, Keeps Neutral Rati..
MT
11/08Radius Health Swings to Q3 Loss as Revenue Falls
MT
11/08RADIUS HEALTH, INC. : Third Quarter 2021 Results - Form 8-K
PU
More news
News in other languages on RADIUS HEALTH, INC.
12/08Les actions du secteur de la santé font grimper les marchés plus larges mercredi en fin..
12/08L'étude de Radius Health sur un traitement potentiel pour les femmes ménopausées souffr..
11/08Radius Health enregistre une perte au troisième trimestre en raison de la baisse des re..
11/08Earnings Flash (RDUS) RADIUS HEALTH affiche un chiffre d'affaires de 56,8 millions de d..
10/20Radius Health et Menarini déclarent que l'essai de phase 3 de l'Elacestrant dans le can..
More news
Analyst Recommendations on RADIUS HEALTH, INC.
More recommendations
Chart RADIUS HEALTH, INC.
Duration : Period :
Radius Health, Inc. Technical Analysis Chart | RDUS | US7504692077 | MarketScreener
Technical analysis trends RADIUS HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 8,01 $
Average target price 19,13 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
George Kelly Martin President, Chief Executive Officer & Director
Steven Helwig CFO, Treasurer & Chief Accounting Officer
Owen Patrick Hughes Chairman
Bruce Mitlak Chief Medical Officer
Averi Price Secretary, Chief Compliance Officer & VP
Sector and Competitors
1st jan.Capi. (M$)
RADIUS HEALTH, INC.-55.15%379
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
VERTEX PHARMACEUTICALS-12.58%52 531